News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bolder BioTechnology, Inc. Awarded National Institutes of Health (NIH) Phase I SBIR Grant To Develop Bioscavenger Protein For Detoxifying Nerve Agents



10/19/2005 5:13:19 PM

WHEAT RIDGE, Colo., Oct. 10 /PRNewswire/ -- Bolder BioTechnology, Inc. today announced that it has been awarded a $121,844 Phase I Small Business Innovation Research (SBIR) grant from The National Institute of General Medical Sciences of The National Institutes of Health. The grant provides funds to optimize the pharmacological properties of a human enzyme, butyrylcholinesterase, which is capable of inactivating toxic organophosphorus nerve agents such as Soman, Sarin and VX. The optimized butyrylcholinesterase protein may have applications in Biodefense as a bioscavenger protein for detoxifying nerve agents, and as a treatment for patients with cocaine or heroin drug overdoses.

The SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs. Companies that successfully meet the goals of the Phase I grant are eligible to apply for an additional $750,000 in Phase II grant support to continue their product development efforts.

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at www.bolderbio.com.

Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.

Bolder BioTechnology, Inc.

CONTACT: Joe Cox, Ph.D., President of Bolder BioTechnology, Inc.,+1-303-420-4420, ext. 101


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES